X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (265) 265
humans (251) 251
oncology (228) 228
male (195) 195
female (194) 194
middle aged (185) 185
aged (174) 174
chemotherapy (123) 123
adult (120) 120
cancer (99) 99
pancreatic cancer (86) 86
pancreatic neoplasms - drug therapy (79) 79
treatment outcome (78) 78
hepatocellular carcinoma (74) 74
deoxycytidine - analogs & derivatives (71) 71
gemcitabine (71) 71
antineoplastic combined chemotherapy protocols - therapeutic use (61) 61
gastroenterology & hepatology (61) 61
survival (58) 58
liver neoplasms - drug therapy (54) 54
aged, 80 and over (52) 52
prognosis (48) 48
5-fluorouracil (47) 47
carcinoma, hepatocellular - drug therapy (47) 47
pancreatic neoplasms - pathology (47) 47
survival rate (47) 47
disease-free survival (45) 45
liver neoplasms - pathology (45) 45
cisplatin (44) 44
carcinoma (43) 43
antineoplastic agents - therapeutic use (42) 42
deoxycytidine - administration & dosage (41) 41
japan (41) 41
liver cancer (41) 41
medicine & public health (41) 41
therapy (41) 41
care and treatment (39) 39
research (39) 39
carcinoma, hepatocellular - pathology (38) 38
clinical trials (38) 38
hepatoma (36) 36
cisplatin - administration & dosage (35) 35
retrospective studies (35) 35
neoplasm staging (34) 34
drug combinations (33) 33
pancreatic neoplasms - mortality (33) 33
deoxycytidine - therapeutic use (32) 32
s-1 (31) 31
sorafenib (31) 31
antimetabolites, antineoplastic - therapeutic use (29) 29
biliary tract neoplasms - drug therapy (29) 29
kaplan-meier estimate (29) 29
pharmacology & pharmacy (29) 29
tegafur - administration & dosage (29) 29
adenocarcinoma (28) 28
adenocarcinoma - drug therapy (28) 28
drug administration schedule (28) 28
patients (28) 28
tumors (28) 28
antineoplastic agents - administration & dosage (27) 27
survival analysis (27) 27
trial (27) 27
analysis (26) 26
liver neoplasms - mortality (26) 26
oxonic acid - administration & dosage (26) 26
pharmacology/toxicology (26) 26
deoxycytidine - adverse effects (25) 25
metastasis (25) 25
antineoplastic agents - adverse effects (24) 24
carcinoma, hepatocellular - mortality (24) 24
antimitotic agents (23) 23
antineoplastic agents (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
cancer research (23) 23
disease progression (23) 23
surgery (23) 23
biliary tract cancer (22) 22
fluorouracil - administration & dosage (22) 22
antimetabolites, antineoplastic - administration & dosage (21) 21
medical prognosis (21) 21
medical research (21) 21
risk factors (21) 21
toxicity (21) 21
cancer therapies (20) 20
pancreatic neoplasms - diagnosis (20) 20
surgical oncology (20) 20
tegafur - adverse effects (20) 20
antimetabolites, antineoplastic - adverse effects (19) 19
combination (19) 19
fluorouracil (19) 19
multicenter (19) 19
oncology, experimental (19) 19
biomarkers, tumor - blood (18) 18
clinical study (18) 18
diagnosis (18) 18
gastroenterology and hepatology (18) 18
oxonic acid - adverse effects (18) 18
pancreatic neoplasms - blood (18) 18
phase-iii trial (18) 18
cancer patients (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii55 - vii55
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 2/2018, Volume 53, Issue 2, pp. 281 - 290
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 859 - 870
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2017, Volume 52, Issue 4, pp. 512 - 519
Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor... 
E7080 | Medicine & Public Health | Tyrosine kinase inhibitor | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Vascular endothelial growth factor inhibitor | Hepatocellular carcinoma | Lenvatinib | Surgical Oncology | MODIFIED RECIST | RESPONSE EVALUATION CRITERIA | SERUM | KINASE INHIBITOR | SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY | ENDOTHELIAL GROWTH-FACTOR | Body Weight | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Carcinoma, Hepatocellular - diagnostic imaging | Young Adult | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Drug Administration Schedule | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Liver Neoplasms - diagnostic imaging | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Quinolines - therapeutic use | Neoplasm Staging | Quinolines - adverse effects | Tyrosine | Complications and side effects | Medical research | Care and treatment | Medicine, Experimental | Hepatoma | Growth factors | Endothelium | Index Medicus | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma ( NEC ) of the digestive system. Clinical data from 258 patients... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Index Medicus | Original
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 6, pp. 514 - 523
Journal Article
Journal of Japanese Society of Gastroenterology, ISSN 0446-6586, 2019, Volume 116, Issue 1, pp. 45 - 51
Journal Article
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, ISSN 0446-6586, 2019, Volume 116, Issue 1, p. 45
Journal Article
Hepatology, ISSN 0270-9139, 04/2014, Volume 59, Issue 4, pp. 1427 - 1434
Journal Article